Novel biomarkers and therapeutic targets for optimizing the therapeutic management of melanomas
about
Epigenetic mechanisms involved in melanoma pathogenesis and chemoresistanceThe Concept of Hormesis in Cancer Therapy - Is Less More?Molecular biomarkers of cancer stem/progenitor cells associated with progression, metastases, and treatment resistance of aggressive cancersDormancy of growth-stunted malignant melanoma: sustainable and smoldering patternsHypoxia-inducing factors as master regulators of stemness properties and altered metabolism of cancer- and metastasis-initiating cellsWithaferin a alone and in combination with cisplatin suppresses growth and metastasis of ovarian cancer by targeting putative cancer stem cellsFluorescently labeled therapeutic antibodies for detection of microscopic melanoma.MicroRNA-143 targets Syndecan-1 to repress cell growth in melanomaLoss of MiR-664 Expression Enhances Cutaneous Malignant Melanoma Proliferation by Upregulating PLP2Surgical resection plus biotherapy/chemotherapy improves survival of hepatic metastatic melanoma.DOXIL when combined with Withaferin A (WFA) targets ALDH1 positive cancer stem cells in ovarian cancermiR-186 suppressed CYLD expression and promoted cell proliferation in human melanomaHonokiol as a Radiosensitizing Agent for Colorectal cancers.Altered gene products involved in the malignant reprogramming of cancer stem/progenitor cells and multitargeted therapies.Targeting RAS/RAF/MEK/ERK signaling in metastatic melanoma.Understanding the colon cancer stem cells and perspectives on treatment.Targeting cancer stem cell-specific markers and/or associated signaling pathways for overcoming cancer drug resistance.Effect of downregulation of ZEB1 on vimentin expression, tumour migration and tumourigenicity of melanoma B16F10 cells and CSCs.Recent Advances in Comprehending the Signaling Pathways Involved in the Progression of Breast Cancer.Molecular signatures associated with tumor-specific immune response in melanoma patients treated with dendritic cell-based immunotherapy.
P2860
Q26778761-338A252D-0D48-49F9-B6D4-B011559A5472Q26800519-40639333-A423-4260-ACCE-FB2B34400FDBQ26822406-8FE5AEC8-83BB-4B65-9067-0D9B4E1FD9E2Q28083204-A7C75297-43A4-44B8-8EED-03A053221F03Q28393898-5B592C44-B168-4146-A43B-25D36079DF8DQ28543359-48F13BAB-4DBA-4369-9E34-1F8CB3604F04Q30543887-A7E3FBAC-DBEA-473E-A9A3-CCFF167CAC83Q35145657-EDFDB90E-A6EA-46A6-8862-D9AB5171952EQ36194074-0CB28FF5-77A1-4B88-843A-8108639B1601Q36507955-30DAA2E3-74A9-4194-8693-EFB50C5ED936Q37276254-8B0135E6-F156-4ED4-A665-82348625BCB4Q37288347-7BF3674E-6EEC-401C-8EC5-8BFB43E4C46AQ37351849-97889407-31D9-459B-A9D8-EBB7765F57ADQ37610799-7517E139-A1B8-485F-AE17-A20A7858519AQ38124821-06CE99BD-CF6B-49E9-A69D-C0CECD675B3DQ38356774-7F7347BE-2E12-492E-B851-A066487601BEQ38937280-C0DFC154-4CCD-4EE9-92F4-4991B151FFB4Q39043081-AE221D33-E99E-47CB-AE0E-80559F8CE196Q47143199-149DEBAF-A4B7-44BC-B169-42833E3DDCCAQ52571242-65EE13A1-A2E8-4223-8A83-AF55669EC731
P2860
Novel biomarkers and therapeutic targets for optimizing the therapeutic management of melanomas
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Novel biomarkers and therapeut ...... peutic management of melanomas
@ast
Novel biomarkers and therapeut ...... peutic management of melanomas
@en
type
label
Novel biomarkers and therapeut ...... peutic management of melanomas
@ast
Novel biomarkers and therapeut ...... peutic management of melanomas
@en
prefLabel
Novel biomarkers and therapeut ...... peutic management of melanomas
@ast
Novel biomarkers and therapeut ...... peutic management of melanomas
@en
P2860
P356
P1476
Novel biomarkers and therapeut ...... peutic management of melanomas
@en
P2093
Murielle Mimeault
Surinder K Batra
P2860
P356
10.5306/WJCO.V3.I3.32
P577
2012-03-01T00:00:00Z